/
BFRI
$1.02+$0.05 (+5.05%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$12.4M
13M shares
52-week range
$0.55 – $1.19
73% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
4.04%
Moderate
Price (6 mo)
Loading chart…
Change$-87.18
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $26.2M | $18.8M | $24.1M | $28.7M | $34.1M | $37.3M | $41.7M |
| Cost of revenue | $12.4M | $9.1M | $12.7M | $15.2M | $17.4M | $18.6M | $8.9M |
| Gross profit | $13.8M | $9.8M | $11.4M | $13.5M | $16.6M | $18.7M | $32.8M |
| Gross margin | 52.6% | 51.9% | 47.1% | 47.0% | 48.8% | 50.1% | 78.7% |
| R&D | $0 | $0 | $0 | $0 | $77.0K | $2.1M | $3.7M |
| Operating income | −$14.9M | −$9.6M | −$25.2M | −$18.6M | −$22.7M | −$17.2M | −$9.1M |
| EBITDA | −$8.1M | −$7.5M | −$36.8M | $934.0K | −$18.5M | −$14.4M | −$9.2M |
| Net income | −$11.0M | −$11.0M | −$37.7M | −$640.0K | −$20.1M | −$17.8M | −$10.5M |
| Net margin | -41.9% | -58.3% | -156.5% | -2.2% | -59.1% | -47.6% | -25.3% |
| EPS (diluted) | -18.09 | -18.94 | -44.10 | -0.61 | -13.02 | -3.22 | -0.90 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $46M | $-0.23 | $-0.23–$-0.23 | 1 |
| 2027 | $53M | $0.19 | $0.19–$0.19 | 1 |
| 2028 | $64M | $0.22 | $0.15–$0.29 | 2 |
| 2029 | $81M | $0.34 | $0.34–$0.34 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Biofrontera Inc. Common Stock
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.
www.biofrontera-us.com- Employees
- 94
- IPO / List date
- Oct 29, 2021
- HQ
- WOBURN, MA
Held by traders on TradeandTell
No one on the platform currently holds BFRI.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 18,700 | $18.4K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2023-07-05 | 1-for-20reverse |
Recent trades on TradeandTell
No one on the platform has traded BFRI yet.
